- Home
- IMCR vs BCRX Comparison
IMCR vs BCRX Comparison
Compare IMCR & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- BCRX
- Stock Information
- Founded
- IMCR 2008
- BCRX 1986
- Country
- IMCR United Kingdom
- BCRX United States
- Employees
- IMCR N/A
- BCRX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMCR Health Care
- BCRX Health Care
- Exchange
- IMCR Nasdaq
- BCRX Nasdaq
- Market Cap
- IMCR 1.8B
- BCRX 1.8B
- IPO Year
- IMCR 2021
- BCRX 1994
- Fundamental
- Price
- IMCR $37.20
- BCRX $8.27
- Analyst Decision
- IMCR Buy
- BCRX Strong Buy
- Analyst Count
- IMCR 9
- BCRX 10
- Target Price
- IMCR $57.00
- BCRX $16.70
- AVG Volume (30 Days)
- IMCR 284.7K
- BCRX 2.2M
- Earning Date
- IMCR 11-05-2025
- BCRX 11-03-2025
- Dividend Yield
- IMCR N/A
- BCRX N/A
- EPS Growth
- IMCR N/A
- BCRX N/A
- EPS
- IMCR N/A
- BCRX N/A
- Revenue
- IMCR $356,145,000.00
- BCRX $557,506,000.00
- Revenue This Year
- IMCR $31.83
- BCRX $41.37
- Revenue Next Year
- IMCR $8.50
- BCRX $7.56
- P/E Ratio
- IMCR N/A
- BCRX N/A
- Revenue Growth
- IMCR 26.78
- BCRX 45.85
- 52 Week Low
- IMCR $23.15
- BCRX $6.02
- 52 Week High
- IMCR $39.33
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- IMCR 76.55
- BCRX 43.55
- Support Level
- IMCR $31.85
- BCRX $8.02
- Resistance Level
- IMCR $33.08
- BCRX $8.68
- Average True Range (ATR)
- IMCR 1.28
- BCRX 0.22
- MACD
- IMCR 0.50
- BCRX 0.01
- Stochastic Oscillator
- IMCR 100.00
- BCRX 37.88
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.